1058 DVT And Abdominoplasty: A Holistic 8-Point Protocol-Based Approach to Prevent DVT

Clues to DVT pathogenesis.

In this issue of Blood, Brill and colleagues demonstrate that von Willebrand factor (VWF) release and subsequent platelet adhesion to endothelial cells are required for thrombus formation in a mouse model of deep venous thrombosis (DVT).

Lysis and Devices for Dvt

DVT: A New Era in Anticoagulation Therapy DVT: A New Era in Anticoagulant Therapy

March is deep vein thrombosis awareness month in the United States. To mark this event, this issue of Arteriosclerosis, Thrombosis, and Vascular Biology contains a series of reviews on new anticoagulants that either are in development or have been approved for clinical use. Particularly exciting are the new oral inhibitors of thrombin (dabigatran etexilate) and factor Xa (rivaroxaban). Thrombos...

DVT: A New Era in Anticoagulant Therapy DVT: A New Era in Anticoagulant Therapy

Thrombosis is the leading cause of morbidity and mortality in the Western world. Arterial thrombosis leads to myocardial infarction and stroke. Arterial clots are platelet-rich and fibrin-poor (so-called white clots). They are generated at sites of vascular injury under high shear rates and are prevented or treated with antiplatelet drugs.1 However, because of the fact that the thrombin is a po...

Endovascular Therapies in Acute DVT

Traditionally, DVTs have been treated with the use of oral anticoagulation medication (such as warfarin) for a period of 6 months. However, this is associated with a high risk for recurrent thrombosis, and approximately one third will develop post thrombotic syndrome despite treatment (Prandoni et al 1996). The recurrence of DVT is thought to be related to damage to the venous valves during an ...